Cited by 15,256

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Open access

Wanchoo, Rimda, Karam, Sabine, Uppal, Nupur N., Barta, Valerie S., Deray, Gilbert, Devoe, Craig, Launay-Vacher, Vincent, Jhaveri, Kenar D., on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors·2017·American Journal of Nephrology

DOI 10.1159/000455014

Open this paper in CoChat — free account

Abstract

Background: Cancer immunotherapy, such as anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed death 1 (PD-1), has revolutionized the treatment of malignancies by engaging the patient's own immune system against the tumor rather than targeting the cancer directly. These therapies have demonstrated a significant benefit in the treatment of melanomas and other cancers. Summary: In order to provide an extensive overview of the renal toxicities induced by these agents, a Medline search was conducted of published literature related to ipilimumab-, pembrolizumab-, and nivolumab-induced kidney toxicity. In addition, primary data from the initial clinical trials of these agents and the FDA adverse reporting system database were also reviewed to determine renal adverse events. Acute interstitial nephritis (AIN), podocytopathy, and hyponatremia were toxicities caused by ipilimumab. The main adverse effect associated with both the PD-1 inhibitors was AIN. The onset of kidney injury seen with PD-1 inhibitors is usually late (3-10 months) compared to CTLA-4 antagonists related renal injury, which happens earlier (2-3 months). PD-1 as opposed to CTLA-4 inhibitors has been associated with kidney rejection in transplantation. Steroids appear to be effective in treating the immune-related adverse effects noted with these agents. Key Message: Although initially thought to be rare, the incidence rates of renal toxicities might be higher (9.9-29%) as identified by recent studies. As a result, obtaining knowledge about renal toxicities of immune checkpoint inhibitors is extremely important.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1159/000455014

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70054-9 · Cited by 1,415

Show all 14 references

Research works printed but not linked: 35

10.1016/j.coi.2015.11.001 · DOI
10.1016/S0065-2776(06)90001-7 · DOI · Paper page
10.1177/1060028015586218 · DOI
10.18632/oncotarget.2980 · DOI
10.1007/s11912-012-0284-2 · DOI
10.1016/j.kint.2016.04.008 · DOI · Paper page
10.1371/journal.pone.0053745 · DOI · Paper page
10.1097/MJT.0b013e3182a32ddc · DOI
10.1093/annonc/mdq013 · DOI · Paper page
10.1056/NEJMc0904283 · DOI · Paper page
10.1200/JCO.2011.41.4359 · DOI
10.1007/s10637-014-0092-7 · DOI
10.1016/j.kint.2015.11.028 · DOI
10.1007/s12032-010-9794-7 · DOI
10.1016/j.clineuro.2014.06.011 · DOI
10.1158/1078-0432.CCR-14-2607 · DOI · Paper page
10.1016/S0140-6736(14)60958-2 · DOI · Paper page
10.1016/S1470-2045(15)00083-2 · DOI · Paper page
10.1158/2326-6066.CIR-13-0146 · DOI
10.1053/j.ajkd.2016.02.057 · DOI · Paper page
10.1016/j.ctrv.2016.02.003 · DOI · Paper page
10.1200/JCO.2014.58.3708 · DOI · Paper page
10.1200/JCO.2013.53.0105 · DOI · Paper page
10.1016/S1470-2045(15)70076-8 · DOI · Paper page
10.1093/ckj/sfw024 · DOI
10.1007/s11523-016-0426-9 · DOI
10.4049/jimmunol.1400497 · DOI
10.4049/jimmunol.179.11.7466 · DOI
10.1093/ndt/gfl818 · DOI
10.1681/ASN.2006050418 · DOI · Paper page
10.1200/JCO.2013.49.2314 · DOI
10.1056/NEJMc1509268 · DOI · Paper page
10.1111/ajt.13711 · DOI
10.1093/annonc/mdw130 · DOI
10.1111/ajt.13786 · DOI

Items 601–647 of 647

Immune checkpoint inhibitors and their interaction with proton pump inhibitors-related interstitial nephritis
Miao, J., & Herrmann, S. M. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad109 · Cited by 31
Immunotherapy in Glioblastoma: A Clinical Perspective
Desbaillets, N., & Hottinger, A. F. (2021) · Cancers · doi:10.3390/cancers13153721 · Cited by 31
Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events
Hoefsmit, E. P., Rozeman, E. A., Haanen, J. B. A. G., & Blank, C. U. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000472 · Cited by 29
A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA)
Meindl-Beinker, N. M., Betge, J., Gutting, T., Burgermeister, E., Belle, S., Zhan, T., Schulte, N., Maenz, M., Ebert, M. P., & Haertel, N. (2019) · BMC Cancer · doi:10.1186/s12885-019-5446-2 · Cited by 30
The impact of immunosenescence on the efficacy of immune checkpoint inhibitors in melanoma patients: a meta-analysis
Li, P., Yang, X., Feng, Y., Wu, L., Ma, W., Ding, G., Wei, Y., & Sun, L. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s165368 · Cited by 29
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study
Sanborn, R. E., Hamid, O., de Vries, E. G., Ott, P. A., Garcia-Corbacho, J., Boni, V., Bendell, J., Autio, K. A., Cho, D. C., Plummer, R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002446 · Cited by 28
Potential Risk Factors for Nivolumab-induced Thyroid Dysfunction
(2017) · In Vivo · doi:10.21873/invivo.11195 · Cited by 28
Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era?
Ou, S.-H., & Soo, R. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s52787 · Cited by 28
Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword
Kamrani, S., Naseramini, R., Khani, P., Razavi, Z. S., Afkhami, H., Atashzar, M. R., Nasri, F., Alavimanesh, S., Saeidi, F., & Ronaghi, H. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03741-x · Cited by 27
Increased tumor vascularization is associated with the amount of immune competent PD‑1 positive cells in testicular germ cell tumors
Jennewein, L., Bartsch, G., Gust, K., Kvasnicka, H., Haferkamp, A., Blaheta, R., Mittelbronn, M., Harter, P., & Mani, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.8597 · Cited by 27
Intermittent hypoxia enhances the tumor programmed death ligand 1 expression in a mouse model of sleep apnea
Huang, M.-H., Zhang, X.-B., Wang, H.-L., Li, L.-X., Zeng, Y.-M., Wang, M., & Zeng, H.-Q. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.01.44 · Cited by 25
Incidence of Thyroid Function Test Abnormalities in Patients Receiving Immune-Checkpoint Inhibitors for Cancer Treatment
Patel, N. S., Oury, A., Daniels, G. A., Bazhenova, L., & Patel, S. P. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0375 · Cited by 25
Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
Zhao, D., Li, H., Mambetsariev, I., Mirzapoiazova, T., Chen, C., Fricke, J., Kulkarni, P., Villaflor, V., Arvanitis, L., Hamilton, S., et al. (2022) · Cancers · doi:10.3390/cancers14194933 · Cited by 24
Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer
Koyama, J., Horiike, A., Yoshizawa, T., Dotsu, Y., Ariyasu, R., Saiki, M., Sonoda, T., Uchibori, K., Nishikawa, S., Kitazono, S., et al. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.04.102 · Cited by 23
Checkpoint inhibitor use in two heart transplant patients with metastatic melanoma and review of high-risk populations
Grant, M. J., DeVito, N., & Salama, A. K. S. (2018) · Melanoma Management · doi:10.2217/mmt-2018-0004 · Cited by 24
A Paradoxical Role for Regulatory T Cells in the Tumor Microenvironment of Pancreatic Cancer
Brouwer, T., Ijsselsteijn, M., Oosting, J., Ruano, D., van der Ploeg, M., Dijk, F., Bonsing, B., Fariña, A., Morreau, H., Vahrmeijer, A., et al. (2022) · Cancers · doi:10.3390/cancers14163862 · Cited by 24
Novel Therapies in Platinum-refractory Metastatic Germ Cell Tumor: A Case Report with a Focus on a PD-1 Inhibitor
Loh, K. P., & Fung, C. (2017) · Rare Tumors · doi:10.4081/rt.2017.6867 · Cited by 23
Induction of T-Cell Infiltration and Programmed Death Ligand 2 Expression by Adeno-Associated Virus in Rhesus Macaque Skeletal Muscle and Modulation by Prednisone
Cramer, M. L., Shao, G., Rodino-Klapac, L. R., Chicoine, L. G., & Martin, P. T. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.113 · Cited by 22
Systemic Inflammation/Nutritional Status Scores Are Prognostic but Not Predictive in Metastatic Non-Small-Cell Lung Cancer Treated with First-Line Immune Checkpoint Inhibitors
Mahiat, C., Bihin, B., Duplaquet, F., Stanciu Pop, C., Dupont, M., Vander Borght, T., Rondelet, B., Vanderick, J., André, B., Pirard, L., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043618 · Cited by 23
Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer
Corallo, S., D’Argento, E., Strippoli, A., Basso, M., Monterisi, S., Rossi, S., Cassano, A., & Barone, C. M. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0479-4 · Cited by 22
Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression
Ligero, M., Serna, G., El Nahhas, O. S. M., Sansano, I., Mauchanski, S., Viaplana, C., Calderaro, J., Toledo, R. A., Dienstmann, R., Vanguri, R. S., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0287 · Cited by 22
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers
Saturno, G., Lopes, F., Niculescu-Duvaz, I., Niculescu-Duvaz, D., Zambon, A., Davies, L., Johnson, L., Preece, N., Lee, R., Viros, A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.483 · Cited by 21
Metabolic Remodelling: An Accomplice for New Therapeutic Strategies to Fight Lung Cancer
Mendes, C., & Serpa, J. (2019) · Antioxidants · doi:10.3390/antiox8120603 · Cited by 21
Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non‐small cell lung cancer
Katayama, Y., Yamada, T., Tanimura, K., Yoshimura, A., Takeda, T., Chihara, Y., Tamiya, N., Kaneko, Y., Uchino, J., & Takayama, K. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.12969 · Cited by 20
Acral melanoma in skin of color: current insights and future directions: a narrative review
Nadelmann, E., Singh, A., Abbruzzese, M., Adeuyan, O., Kenchappa, D., Kovrizhkin, K., Lightman, M., Samouha, A., Tao, K., Yun, J., et al. (2025) · Cancers · doi:10.3390/cancers17030468 · Cited by 20
Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?
Tsironis, G., Ziogas, D. C., Kyriazoglou, A., Lykka, M., Koutsoukos, K., Bamias, A., & Dimopoulos, M.-A. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.02.18 · Cited by 19
Expression Analysis of Autophagy Related Markers LC3B, p62 and HMGB1 Indicate an Autophagy-Independent Negative Prognostic Impact of High p62 Expression in Pulmonary Squamous Cell Carcinomas
Langer, R., Neppl, C., Keller, M. D., Schmid, R. A., Tschan, M. P., & Berezowska, S. (2018) · Cancers · doi:10.3390/cancers10090281 · Cited by 17
Challenges and Opportunities for Quantitative Clinical Pharmacology in Cancer Immunotherapy: Something Old, Something New, Something Borrowed, and Something Blue
Stroh, M., Carlile, D., Li, C.-C., Wagg, J., Ribba, B., Ramanujan, S., Jin, J., Xu, J., Charoin, J.-E., Xhu, Z.-X., et al. (2015) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12014 · Cited by 16
Targeting Cross-Presentation as a Route to Improve the Efficiency of Peptide-Based Cancer Vaccines
Wylie, B., Ong, F., Belhoul-Fakir, H., Priebatsch, K., Bogdawa, H., Stirnweiss, A., Watt, P., Cunningham, P., Stone, S. R., & Waithman, J. (2021) · Cancers · doi:10.3390/cancers13246189 · Cited by 16
Immunological mechanisms underlying clinical phenotypes and noninvasive diagnosis of immune checkpoint inhibitor-induced kidney disease
Seethapathy, H., Mistry, K., & Sise, M. E. (2023) · Immunological Reviews · doi:10.1111/imr.13243 · Cited by 15
Gut microbiota diversity and composition in predicting immunotherapy response and immunotherapy-related colitis in melanoma patients: A systematic review
Oey, O., Liu, Y.-Y., Sunjaya, A. F., Simadibrata, D. M., Khattak, M. A., & Gray, E. (2022) · World Journal of Clinical Oncology · doi:10.5306/wjco.v13.i11.929 · Cited by 15
Deep learning analysis of histopathological images predicts immunotherapy prognosis and reveals tumour microenvironment features in non-small cell lung cancer
Wang, Y., Ju, X., Hua, R., Chen, J., Dai, X., Liu, L., Wang, G., Bai, Y., Hu, H., & Li, X. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02856-8 · Cited by 18
Recurrent acute interstitial nephritis: what lies beneath
Caravaca-Fontán, F., Shabaka, A., Sánchez-Álamo, B., de Lorenzo, A., Díaz, M., Blasco, M., Rodríguez, E., Sierra-Carpio, M., Malek Marín, T., Urrestarazú, A., et al. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfaa018 · Cited by 15
The diagnosis of acute interstitial nephritis caused by infection versus antibiotic-induced interstitial nephritis: a narrative review
Muhammad, A., Zhang, Y., Huang, L., Yuan, Q., Wang, W., Pu, J., Lin, W., Tang, R., & Xiao, X. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae054 · Cited by 13
Associations between HIFs and tumor immune checkpoints: mechanism and therapy
Liu, J., Jiang, Y., Chen, L., Qian, Z., & Zhang, Y. (2024) · Discover Oncology · doi:10.1007/s12672-023-00836-7 · Cited by 13
Case Report: Dual Checkpoint Inhibition in Advanced Metastatic Osteosarcoma Results in Remission of All Tumor Manifestations—A Report of a Stunning Success in a 37-Year-Old Patient
Sterz, U., Grube, M., Herr, W., Menhart, K., Wendl, C., & Vogelhuber, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.684733 · Cited by 12
The Gut Microbiome and Metastatic Renal Cell Carcinoma
Meza, L., Feng, M., Lee, K., Sperandio, R., & Pal, S. K. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041502 · Cited by 12
Expression of the immune checkpoint receptor TIGIT in seminoma
Hinsch, A., Blessin, N., Simon, R., Kluth, M., Fischer, K., Hube‑Magg, C., Li, W., Makrypidi‑Fraune, G., Wellge, B., Mandelkow, T., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.10428 · Cited by 12
Successful use of adalimumab in immune checkpoint inhibitor-associated inflammatory arthritis
Oke, A. R., Wheater, M., Karydis, I., & Wallis, D. (2018) · Rheumatology Advances in Practice · doi:10.1093/rap/rky001 · Cited by 11
Clinical and Biological Activity of Chemoimmunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium
Barber, E. L., Chen, S., Pineda, M. J., Robertson, S. E., Hill, E. K., Teoh, D., Schilder, J., O'Shea, K. L., Kocherginsky, M., Zhang, B., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0147 · Cited by 9
Recurrent Adrenergic Stress Provokes Persistent Myocarditis in PD-1–Deficient Mice
Hayashi, T., Lim, K. R. Q., Kovacs, A., & Mann, D. L. (2023) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2023.07.012 · Cited by 8
Efficacy and safety of trifluridine/tipiracil (TAS-102) in patients with metastatic colorectal cancer: A systematic review and meta-analysis
Huang, F., Yang, H., Bao, W., Bin, Y., Zhou, S., Wang, M., & Lv, X. (2023) · Clinical and Translational Oncology · doi:10.1007/s12094-023-03268-5 · Cited by 6
The development of a t umor‐associated autoantibodies panel to predict clinical outcomes for immune checkpoint i nhibitor‐based treatment in patients with advanced n on‐small‐cell lung cancer
Zhao, J., Wu, Y., Yue, Y., Chen, M., Xu, Y., Liu, X., Liu, X., Gao, X., Wang, H., Si, X., et al. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.14772 · Cited by 6
Safety and tolerability of first‐line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma
Lee, D. H., Kim, H. R., Keam, B., Kato, K., Kuboki, Y., Gao, H., Yovine, A., Robbins, S. H., & Ahn, M. (2023) · Cancer Medicine · doi:10.1002/cam4.6260 · Cited by 6
Obstruction of BRAFV600E transcription by complementary PNA oligomers as a means to inhibit BRAF-mutant melanoma growth
Rothman, J. H., Surriga, O., de Stanchina, E., Vasudeva, S. D., & Schwartz, G. K. (2017) · Cancer Gene Therapy · doi:10.1038/cgt.2017.34 · Cited by 4
PathNetDRP: a novel biomarker discovery framework using pathway and protein–protein interaction networks for immune checkpoint inhibitor response prediction
Lee, D., Ahn, J., & Choi, J. (2025) · BMC Bioinformatics · doi:10.1186/s12859-025-06125-0 · Cited by 4
A novel bioinformatics pipeline for the identification of immune inhibitory receptors as potential therapeutic targets
Singh, A., Miranda Bedate, A., von Richthofen, H. J., Vijver, S. V., van der Vlist, M., Kuhn, R., Yermanos, A., Kuball, J. J., Kesmir, C., Pascoal Ramos, M. I., et al. (2024) · eLife · doi:10.7554/elife.92870 · Cited by 4

Authors: Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors
Venue: American Journal of Nephrology
Publisher: S. Karger AG
Published: 2017
Volume: 45
Issue: 2
Pages: 160-169
ISSN: 0250-8095 (ISSN-L)
1421-9670
DOI: 10.1159/000455014
OpenAlex: W2572174216
Cited by: 15,256
References: 14
FWCI: 180.98
Type: journal article
Language: en
Open access: bronze
Licence: www.karger.com/Services/SiteLicenses (vor)
www.karger.com/Services/SiteLicenses (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Metadata

Record

About these checks

Data sources